Pharmaceutical, medical device and biotechnology enterprises can leverage a solid intellectual property strategy to capitalize their businesses and the commercialization process. I have worked closely with business and regulatory attorneys that serve clients ranging in size from small start-up entities to very large public companies to fund the commercialization of their products. This experience has included mergers and acquisitions, debt and equity financing, securities, corporate governance, executive employment agreements, regulatory matters, partnerships and joint ventures, and taxation. Our experience also includes conducting intellectual property due diligence as a part of initial public offerings (IPOs), private placements, mergers, acquisitions, and spin-outs. I have also represented lenders, borrowers, investors, and life sciences growth companies in structuring, negotiating, and closing a wide variety of financing and capital formation transactions, including senior term and revolving credit facilities, subordinated debt, convertible debt, venture and private equity financing, and restructurings.
My experience includes working directly with investors in preparing: Legal opinions including patentability, infringement, validity, and freedom-to-operate opinions Patent portfolio audits Patent landscape analyses Technology clearance studies My practice has also involved assisting clients with identifying potential sources of capital, market conditions, and in determining what technologies may be over- or under-invested, and in developing venture management strategies. By doing so, the information my clients obtain from angel, corporate, and venture investors can be leveraged to more effectively develop intellectual property strategies that protect technologies better predicted to be "investable."